CELL CENTER CC
Cell
therapies
Cell therapies offer new treatment options for patients with cancer. The Champalimaud Foundation recognizes the unmet need access to cell therapies and created the CELL CENTER (CC). It consists of a state-of-the-art GMP facility with 11 production rooms to produce non-genetically modified and genetically modified cells. The CC GMP facility is accompanied by the CC manufacturing facility, a pre-clinical and process development unit. Together, these facilities create a seamless functional entity to accelerate innovative cell therapies.
Development and manufacturing: seamless
The CC operates at the interface of biologically and clinically relevant preclinical research development platforms, high content ex vivo modelling of biological readouts, diligent advanced smart cell manufacturing with the aim to make successful processes transferable. The CC development unit brings together scientific innovations and a strong interface with clinical medicine. The CC manufacturing unit is a dedicated GMP structure with the highest industrial standard to facilitate access to cell therapy and democratize modern cell therapies. We aim to advance innovative science and combinatorial therapies with academic and commercial partners in order to change the clinical outcome for patients with a cancer diagnosis.
Manufacturing facility
The CC is constructed as a multi-purpose industry-grade 500 m2 / 5 400 sq ft facility along with a quality control laboratory with 100 sq meters (1 100 sq ft) featuring an all-integrated e-batch record system from MODA, a smart, integrated batch-record system solution. The Champalimaud Foundation obtained a transformative agreement with the university of Stanford and is now the sole licensee for a comprehensive portfolio of synthetic biology engineering applications spanning all therapeutic fields. The Foundation has further solidified its position to develop and implement clinically relevant cell therapies by acquiring a patent portfolio from Refuge to accelerate development of safe and promising cell therapies in clinical trials with non-commercial and commercial partners.
Development and manufacturing: seamless
The CC operates at the interface of biologically and clinically relevant preclinical research development platforms, high content ex vivo modelling of biological readouts, diligent advanced smart cell manufacturing with the aim to make successful processes transferable. The CC development unit brings together scientific innovations and a strong interface with clinical medicine. The CC manufacturing unit is a dedicated GMP structure with the highest industrial standard to facilitate access to cell therapy and democratize modern cell therapies. We aim to advance innovative science and combinatorial therapies with academic and commercial partners in order to change the clinical outcome for patients with a cancer diagnosis.
TEAM
The CC is supervised and guided from an internationally highly recognized scientific and clinical advisory team:
Prof Christoph Huber
Founder BioNtech
Prof Dolores Schendel
CSO Medigene
Prof Kees Melief
CIMT
Philipp Meyer-Schmeling
CEO NOA Technologies
Progress Education Training
Education – Training
CIMT summer school
CIMT cancer cell therapy summit
Press Releases
MODA
Stanford license
CELL CENTER
FACILITIES
